Erbitux Approved as First-Line Treatment

The FDA has approved Erbitux™ (cetuximab) in combination with FOLFIRI for first-line treatment of patients with metastatic colorectal cancer whose tumors have a wild-type (WT) KRAS gene.  Erbitux was first approved in 2004 for patients whose cancer was not responding to…  Read More

Highlights from ASCO 2011

While there weren’t new blockbuster announcements for colorectal cancer this year at the American Society for Clinical Oncology’s (ASCO) Annual Meeting, there was plenty of focus on making what we already have work better and on choosing the patients who…  Read More

Personalizing Personalized Medicine

On Monday, April 25th, Fight Colorectal Cancer held a free patient webinar that tackled the somewhat complex but fascinating topic of personalized medicine. Personalized medicine is what the cancer community calls treatments that are tailored to each patient’s genetic makeup.…  Read More

Value of KRAS and BRAF Mutations in Forecasting Survival

For stage II and III colon cancer, a tumor mutation in the KRAS gene does not impact either relapse-free survival or overall survival. BRAF mutations, which are less common, don’t help with prognosis for relapse-free survival, but do provide information…  Read More

CancerCare Workshop on KRAS on November 5

Join a CancerCare Telephone Education Workshop on November 5th to learn more about KRAS and colon cancer. Medical Update on Colon Cancer: Understanding K-RAS November 5, 2009 1:30 pm to 2:30 pm Registration required